Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

In the latest trading session, Astrazeneca (AZN) closed at $75.57, marking a +1.79% move from the previous day.

AstraZeneca is Thursday's pick for IBD 50 Growth Stocks To Watch as the biopharmaceutical name is holding up relatively well ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...

With this approval, durvalumab can now be used for treating patients with limited-stage small cell lung cancer (LS-SCLC) ...

Harvey Jones is looking for UK stocks to add to this year's ISA, and decided to call in some assistance from artificial ...

Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.

UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...

Our writer examines the losses that global stock markets have suffered and ways UK investors can prepare to shield themselves ...

In the FTSE All-Share, DFS Furniture jumped 11% or 13.8p to 145p after reporting an acceleration in order intake at the start ...

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of ...

Retail investors have reduced their stakes in 63 small and midcap stocks, which saw declines between 61% and 20% in 2025. The ...